{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-000083","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.751369+00:00","generated_at":"2026-06-27T20:20:19.954261+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xilio Therapeutics Appoints Yuan Xu, Ph.D., to Board of Directors","bullets":["Board expanded from 8 to 9 directors; Dr. Xu appointed as Class II director effective Jan 4, 2022.","Dr. Xu is former CEO of Legend Biotech and held senior roles at Merck, Gilead, Novartis.","Her appointment comes as Xilio expects initial data readouts for XTX101 and XTX202 in 2022.","Dr. Xu will receive standard non-employee director compensation and enter indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-000083","json":"https://secwatch.observer/filing/0001558370-22-000083.json","markdown":"https://secwatch.observer/filing/0001558370-22-000083.md","text":"https://secwatch.observer/filing/0001558370-22-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/0001558370-22-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/xlo-20220104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:20:19.954261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37fd0d76cf","claim":"Yuan Xu was appointed as Director at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective January 4, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Yuan Xu, Ph.D. to fill a newly created vacancy on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/0001558370-22-000083-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}